Aluminum Corporation of China Ltd (ACH) 7.49 $ACH
Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis
Marketwire Canada - Wed Jun 01, 2:29PM CDT
TORONTO, ONTARIO--(Marketwired - Jun 1, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Commission has designated AB569 as an orphan medicinal product in the European Union for the treatment of patients with cystic fibrosis (CF).
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Research and Markets - China Rare Earth Industry Analysis - Trends, Technologies & Opportunities Report 2011-2020 - Key Vendors: Aluminum Corp of China, Ganzhou Rare Earth Group, Guangdong Rare Earth Industry Group
PR Newswire Europe - Thu Apr 28, 7:10AM CDT
DUBLIN, April 28, 2016 /PRNewswire/ --
ACH: 7.49 (-0.38)
Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis
Marketwired - Tue Apr 26, 7:34AM CDT
Arch Biopartners Inc. (Arch or the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), a portfolio based biotechnology company, today announced the European Medicines Authority (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending AB569 for designation as an orphan medicinal product for the treatment of patients with cystic fibrosis (CF).
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Annual Report on Form 20-F for Fiscal Year 2015 of Aluminum Corporation of China Limited Now Available
JCN Newswire - Sun Apr 17, 9:21PM CDT
BEIJING, Apr 18, 2016 - (ACN Newswire) - Aluminum Corporation of China Limited (the "Company"; NYSE "ACH"; SEHK "2600"; SSE "601600"
announces that the Company's annual report for the 2015 fiscal year filed with the SEC on April 15, 2016 can be accessed via the following link: http://www.chalco.com.cn/zlgfen/rootfiles/201...914893.pdf
ACH: 7.49 (-0.38)
Synthesis Energy Systems, Inc. Reports Largest of Three Aluminum Corporation of China Industrial Fuel Facilities, in Henan Province, Enters Commissioning Phase
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Synthesis Energy Systems, Inc. (SES) (NASDAQ:SYMX), the global leader of full-range feedstock flexibility in advanced energy gasification technology, producing clean and economical syngas to replace expensive imported natural gas and LNG based energy, reported a progress update related to its Tianwo-SES Clean Energy Technologies Company Joint Venture in China. The largest of the three previously announced natural gas replacement projects licensed by Tianwo-SES and under construction for Aluminum Corporation of China Limited (NYSE:ACH) (HKEx:2600) (SSE:601600), and the final project of this order, has entered the commissioning phase. Members of SES's Zao Zhuang New Gas Company Joint Venture are onsite at the facility, located in Henan Province, to support the commissioning and startup. Initial syngas production from two of Henan's four SES Gasification Technology (SGT) systems was achieved in March.
ACH: 7.49 (-0.38), SYMX: 1.05 (-0.01)
Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569
Marketwire Canada - Wed Mar 16, 2:00AM CDT
Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has entered into an exclusive license agreement with the University of Cincinnati (UC) for AB569, a new candidate drug to treat Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
BUYINS.NET: EWZ, ACH, ADRE, ASX, MKSI, AMKR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Feb 10, 6:04AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Ishares Msci Brazil Index Fund (NYSE:EWZ), Arch Biopartners Inc (NYSE:ACH), BLRDS Emerging Markets 50 ADR Index Fund (NASDAQ:ADRE), Advanced Semiconductor Engineering Inc (NYSE:ASX), MKS Instruments Inc (NASDAQ:MKSI), Amkor Technology Inc (NASDAQ:AMKR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMKR: 5.80 (-0.39), ADRE: 29.95 (-1.10), ASX: 5.27 (-0.25), ACH: 7.49 (-0.38), MKSI: 40.79 (-2.04), EWZ: 27.79 (-1.24)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 7.91 (-0.26), ADRO: 10.10 (-0.83), AVXL: 4.55 (+0.28), AMBX: (), ACH: 7.49 (-0.38), AMGN: 146.45 (-5.82), ADMP: 2.73 (-0.07), ABBV: 59.86 (-1.45)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 27.86 (-1.43), ACH: 7.49 (-0.38), CYTR: 2.37 (-0.02), AVEO: 0.95 (-0.03), ARQL: 1.91 (-0.01), CTIC: 0.37 (-0.03), ARRY: 3.45 (-0.13)
Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency
Marketwire Canada - Wed Feb 03, 8:01AM CST
Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced they have submitted an application for orphan drug designation to the European Medicines Authority (EMA) for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Global Rare Earth Elements (REE) Market Growth of 6% CAGR by 2020 - Analysis, Technologies & Forecast Report 2015-2020 - Key Vendors: 3M, Galaxy Resources & XTC
M2 - Tue Jan 26, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/6whwhb/global_rare_earth) has announced the addition of the "Global Rare Earth Elements (REE) Market Segmented by Element, Application and Geography Trends and Forecasts (2015-2020)" report to their offering. The global Rare Earth Elements (REE) market is valued at 5 billion USD in 2014. The market is expected to grow at a CAGR of 6% during the forecast period. As of 2014, the amount of rare earth reserves available worldwide is estimated to be 140 million metric tons. Key Topics Covered: - Market Definition along with identification of key drivers and restraints for the market. - Market analysis with region specific assessments and competition analysis on a global and regional scale. - Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale. - Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares. - Identification and analysis of the Macro and Micro factors that affect the industry on both global and regional scale. Companies Mentioned Include: - 3M - Alkane Resources Ltd. - Aluminum Corporation of China Ltd. - Arafura Resources Limited - Avalon Rare Metals - China Minmetals Corporation - China Nonferrous Metal Industry's Foreign Engineering and Construction Co., Ltd. - Galaxy Resources Ltd. - Ganzhou Rare Earth Group.Co., Ltd. - Orbite Aluminae Inc. - Peak Resources Limited - Quest Rare Minerals Ltd - Rare Element Resources - Rising Nonferrous Metals Share Co., Ltd. - Shin-Etsu Chemical Company - Stans Energy Corp. - Tantalus Rare Earths AG - Ucore Rare Metals INC - XTC Report Structure: 1. Introduction 2. Executive Summary 3. Rare Earth Elements Market 4. Market Dynamics 5. Market Segmentation and Analysis 6. Global Market Analysis (Market size, growth and forecast) 7. Competitive Landscape 8. Company Profiles (Overview, Products & Services, Financials and Recent Developments) 9. Disclaimer For more information visit http://www.researchandmarkets.com/research/6w...rare_earth
ACH: 7.49 (-0.38)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 9.60 (-0.68), PFE: 33.97 (-0.62), AKAO: 3.87 (-0.12), GLYC: 6.90 (-0.16), GSK: 40.80 (-1.76), APHB: 1.56 (-0.04), SRPT: 18.52 (+0.64), ACH: 7.49 (-0.38), AZN: 27.86 (-1.43)
Synthesis Energy Systems, Inc. Heralds New Milestone Achievement at Zibo City Industrial Syngas Facility, First of Three for Aluminum Corporation of China
GlobeNewswire - Tue Jan 19, 7:00AM CST
Synthesis Energy Systems, Inc. (SES) (NASDAQ:SYMX), a global energy and gasification technology company whose advanced SES Gasification Technology (SGT) can produce clean, low-cost syngas for power generation, industrial fuel gas, chemicals and transportation fuels, replacing expensive natural gas, LNG and crude oil based energy, reports a progress update related to the first of three previously announced industrial syngas gasification facilities for Aluminum Corporation of China Limited (CHALCO) (NYSE:ACH) (HKEx:2600) (SSE:601600). The project located in Zibo City, Shandong Province, China and licensed to CHALCO through SES's Tianwo-SES Joint Venture has completed a planned 90-day continuous full-load operation test run successfully supplying stable and reliable industrial syngas to the CHALCO aluminum manufacturing facility. Tianwo-SES provided the SGT technology design and proprietary gasification equipment to the project for the two SGT systems now in operation.
ACH: 7.49 (-0.38), SYMX: 1.05 (-0.01)
Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award
Marketwired - Wed Jan 06, 11:13AM CST
Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), a portfolio based biotechnology company, today announced a Mitacs fellowship with McMaster University for its MetaMx product, a library of synthetic peptides that target and image brain tumour initiating cells. Arch will support Dr. Parvez Vora's Mitacs Elevate Postdoctoral Fellowship to further develop MetaMx, under the supervision of renowned McMaster brain cancer scientist and neurosurgeon, Dr. Sheila Singh. The Mitacs fellowship grant of $32,500 has been augmented by $32,500 from Arch for a total of $65,000 for a period of 1-year.
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis
Marketwire Canada - Wed Jun 01, 2:29PM CDT
TORONTO, ONTARIO--(Marketwired - Jun 1, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Commission has designated AB569 as an orphan medicinal product in the European Union for the treatment of patients with cystic fibrosis (CF).
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Research and Markets - China Rare Earth Industry Analysis - Trends, Technologies & Opportunities Report 2011-2020 - Key Vendors: Aluminum Corp of China, Ganzhou Rare Earth Group, Guangdong Rare Earth Industry Group
PR Newswire Europe - Thu Apr 28, 7:10AM CDT
DUBLIN, April 28, 2016 /PRNewswire/ --
ACH: 7.49 (-0.38)
Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis
Marketwired - Tue Apr 26, 7:34AM CDT
Arch Biopartners Inc. (Arch or the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), a portfolio based biotechnology company, today announced the European Medicines Authority (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending AB569 for designation as an orphan medicinal product for the treatment of patients with cystic fibrosis (CF).
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Annual Report on Form 20-F for Fiscal Year 2015 of Aluminum Corporation of China Limited Now Available
JCN Newswire - Sun Apr 17, 9:21PM CDT
BEIJING, Apr 18, 2016 - (ACN Newswire) - Aluminum Corporation of China Limited (the "Company"; NYSE "ACH"; SEHK "2600"; SSE "601600"
announces that the Company's annual report for the 2015 fiscal year filed with the SEC on April 15, 2016 can be accessed via the following link: http://www.chalco.com.cn/zlgfen/rootfiles/201...914893.pdf ACH: 7.49 (-0.38)
Synthesis Energy Systems, Inc. Reports Largest of Three Aluminum Corporation of China Industrial Fuel Facilities, in Henan Province, Enters Commissioning Phase
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Synthesis Energy Systems, Inc. (SES) (NASDAQ:SYMX), the global leader of full-range feedstock flexibility in advanced energy gasification technology, producing clean and economical syngas to replace expensive imported natural gas and LNG based energy, reported a progress update related to its Tianwo-SES Clean Energy Technologies Company Joint Venture in China. The largest of the three previously announced natural gas replacement projects licensed by Tianwo-SES and under construction for Aluminum Corporation of China Limited (NYSE:ACH) (HKEx:2600) (SSE:601600), and the final project of this order, has entered the commissioning phase. Members of SES's Zao Zhuang New Gas Company Joint Venture are onsite at the facility, located in Henan Province, to support the commissioning and startup. Initial syngas production from two of Henan's four SES Gasification Technology (SGT) systems was achieved in March.
ACH: 7.49 (-0.38), SYMX: 1.05 (-0.01)
Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569
Marketwire Canada - Wed Mar 16, 2:00AM CDT
Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has entered into an exclusive license agreement with the University of Cincinnati (UC) for AB569, a new candidate drug to treat Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
BUYINS.NET: EWZ, ACH, ADRE, ASX, MKSI, AMKR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Feb 10, 6:04AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Ishares Msci Brazil Index Fund (NYSE:EWZ), Arch Biopartners Inc (NYSE:ACH), BLRDS Emerging Markets 50 ADR Index Fund (NASDAQ:ADRE), Advanced Semiconductor Engineering Inc (NYSE:ASX), MKS Instruments Inc (NASDAQ:MKSI), Amkor Technology Inc (NASDAQ:AMKR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMKR: 5.80 (-0.39), ADRE: 29.95 (-1.10), ASX: 5.27 (-0.25), ACH: 7.49 (-0.38), MKSI: 40.79 (-2.04), EWZ: 27.79 (-1.24)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 7.91 (-0.26), ADRO: 10.10 (-0.83), AVXL: 4.55 (+0.28), AMBX: (), ACH: 7.49 (-0.38), AMGN: 146.45 (-5.82), ADMP: 2.73 (-0.07), ABBV: 59.86 (-1.45)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 27.86 (-1.43), ACH: 7.49 (-0.38), CYTR: 2.37 (-0.02), AVEO: 0.95 (-0.03), ARQL: 1.91 (-0.01), CTIC: 0.37 (-0.03), ARRY: 3.45 (-0.13)
Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency
Marketwire Canada - Wed Feb 03, 8:01AM CST
Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced they have submitted an application for orphan drug designation to the European Medicines Authority (EMA) for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
Global Rare Earth Elements (REE) Market Growth of 6% CAGR by 2020 - Analysis, Technologies & Forecast Report 2015-2020 - Key Vendors: 3M, Galaxy Resources & XTC
M2 - Tue Jan 26, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/6whwhb/global_rare_earth) has announced the addition of the "Global Rare Earth Elements (REE) Market Segmented by Element, Application and Geography Trends and Forecasts (2015-2020)" report to their offering. The global Rare Earth Elements (REE) market is valued at 5 billion USD in 2014. The market is expected to grow at a CAGR of 6% during the forecast period. As of 2014, the amount of rare earth reserves available worldwide is estimated to be 140 million metric tons. Key Topics Covered: - Market Definition along with identification of key drivers and restraints for the market. - Market analysis with region specific assessments and competition analysis on a global and regional scale. - Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale. - Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares. - Identification and analysis of the Macro and Micro factors that affect the industry on both global and regional scale. Companies Mentioned Include: - 3M - Alkane Resources Ltd. - Aluminum Corporation of China Ltd. - Arafura Resources Limited - Avalon Rare Metals - China Minmetals Corporation - China Nonferrous Metal Industry's Foreign Engineering and Construction Co., Ltd. - Galaxy Resources Ltd. - Ganzhou Rare Earth Group.Co., Ltd. - Orbite Aluminae Inc. - Peak Resources Limited - Quest Rare Minerals Ltd - Rare Element Resources - Rising Nonferrous Metals Share Co., Ltd. - Shin-Etsu Chemical Company - Stans Energy Corp. - Tantalus Rare Earths AG - Ucore Rare Metals INC - XTC Report Structure: 1. Introduction 2. Executive Summary 3. Rare Earth Elements Market 4. Market Dynamics 5. Market Segmentation and Analysis 6. Global Market Analysis (Market size, growth and forecast) 7. Competitive Landscape 8. Company Profiles (Overview, Products & Services, Financials and Recent Developments) 9. Disclaimer For more information visit http://www.researchandmarkets.com/research/6w...rare_earth
ACH: 7.49 (-0.38)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 9.60 (-0.68), PFE: 33.97 (-0.62), AKAO: 3.87 (-0.12), GLYC: 6.90 (-0.16), GSK: 40.80 (-1.76), APHB: 1.56 (-0.04), SRPT: 18.52 (+0.64), ACH: 7.49 (-0.38), AZN: 27.86 (-1.43)
Synthesis Energy Systems, Inc. Heralds New Milestone Achievement at Zibo City Industrial Syngas Facility, First of Three for Aluminum Corporation of China
GlobeNewswire - Tue Jan 19, 7:00AM CST
Synthesis Energy Systems, Inc. (SES) (NASDAQ:SYMX), a global energy and gasification technology company whose advanced SES Gasification Technology (SGT) can produce clean, low-cost syngas for power generation, industrial fuel gas, chemicals and transportation fuels, replacing expensive natural gas, LNG and crude oil based energy, reports a progress update related to the first of three previously announced industrial syngas gasification facilities for Aluminum Corporation of China Limited (CHALCO) (NYSE:ACH) (HKEx:2600) (SSE:601600). The project located in Zibo City, Shandong Province, China and licensed to CHALCO through SES's Tianwo-SES Joint Venture has completed a planned 90-day continuous full-load operation test run successfully supplying stable and reliable industrial syngas to the CHALCO aluminum manufacturing facility. Tianwo-SES provided the SGT technology design and proprietary gasification equipment to the project for the two SGT systems now in operation.
ACH: 7.49 (-0.38), SYMX: 1.05 (-0.01)
Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award
Marketwired - Wed Jan 06, 11:13AM CST
Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), a portfolio based biotechnology company, today announced a Mitacs fellowship with McMaster University for its MetaMx product, a library of synthetic peptides that target and image brain tumour initiating cells. Arch will support Dr. Parvez Vora's Mitacs Elevate Postdoctoral Fellowship to further develop MetaMx, under the supervision of renowned McMaster brain cancer scientist and neurosurgeon, Dr. Sheila Singh. The Mitacs fellowship grant of $32,500 has been augmented by $32,500 from Arch for a total of $65,000 for a period of 1-year.
ACH.VN: 0.420 (-0.035), ACH: 7.49 (-0.38)
